Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01960387 · ClinicalTrials.gov registry record · Phase 2
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01960387 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 2 participants.
The verdict
NCT01960387, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated treatment regimen in patients with either relapsed/refractory or newly diagnosed AML. For this prospective study, we propose the use of clofarabine and cytarabine for second course induction therapy for patients with persistent AML after treatment with an anthracycline and cytarabine.
Interventions
- DRUG Cytarabine
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01960387
The ClinicalTrials.gov registry entry for NCT01960387 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT01960387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01960387 about?
NCT01960387 is a clinical study titled "Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia". The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated treatment regimen in patients with either relapsed/refractory or newly diagnosed AML. For this prospective study, we propose the use of clofarabine and cytarabine for second course induction therapy for patie...
What is the current status of trial NCT01960387?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01960387?
The interventions under investigation include: Cytarabine (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT01960387?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.